Can Regenerative Medicine Help Arthritis? OA vs. RA — 2 Different Approaches

Regenerative medicine addresses arthritis, but the approach differs fundamentally based on the arthritis type. Osteoarthritis and rheumatoid arthritis involve different underlying mechanisms that require 2 distinct clinical strategies.

Osteoarthritis: The Mechanical and Degenerative Case

Osteoarthritis (OA) involves progressive cartilage degeneration, subchondral bone changes, and synovial inflammation in response to mechanical wear and the biological consequences of cartilage breakdown. OA is not primarily an autoimmune condition.

Regenerative medicine is well-matched to OA. The mechanisms of PRP, exosomes, and stem cells directly address OA's primary pathology:

PRP delivers growth factors (TGF-beta, IGF-1, VEGF) that support chondrocyte activity, reduce synovial inflammation, and stimulate collagen matrix repair in the remaining cartilage. Clinical trials in knee OA show meaningful pain reduction and functional improvement in mild-to-moderate OA.

DayZero™ exosomes deliver anti-inflammatory cytokine modulation and micro-RNA signals that shift the joint environment from degenerative to regenerative. Exosomes at 150 billion to 250 billion particles are used for moderate OA at Rebuild Regen.

DayZero™ umbilical cord stem cells provide the most comprehensive paracrine signal for moderate-to-severe OA with documented cartilage loss on MRI, supervised by [MD_PLACEHOLDER] MD under Florida SB 1768.

The Knee on Trac decompression device is used when compressive loading is a contributing factor.

Rheumatoid Arthritis: The Immune-Mediated Case

Rheumatoid arthritis (RA) is an autoimmune condition where the immune system attacks the synovial membrane, producing systemic inflammation and progressive joint destruction. RA requires disease-modifying antirheumatic drugs (DMARDs) and often biologic immunosuppressants as the foundation of care.

Regenerative medicine's role in RA is secondary, not primary. Patients with RA who are on DMARDs or biologic immunosuppressants require case-by-case evaluation before receiving allogeneic biologics, as the immunosuppressive medications interact with the immune-modulating effects of MSCs in ways that require physician review.

Stable RA patients who are not on contraindicated medications and who have OA superimposed on RA (a common pattern) may benefit from articular PRP or exosome injections for the OA component. This is discussed during the consultation.

How Rebuild Regen Evaluates Arthritis Patients

Arthritis patients at Rebuild Regen Medical Clinic at 3320 N Federal Hwy #101, Lighthouse Point, FL receive a clinical intake that distinguishes OA from RA, reviews imaging, and identifies the appropriate protocol. Lab work including inflammatory markers (CRP, ESR, anti-CCP) distinguishes inflammatory arthritis from degenerative OA when the clinical picture is ambiguous.

When Regenerative Medicine Is Not the Right Primary Treatment for Arthritis

End-stage OA with complete joint space loss (bone-on-bone) where arthroplasty is indicated, active RA flare with high inflammatory burden, and patients on biologic immunosuppressants that preclude safe allogeneic biologics administration are situations where Rebuild Regen directs patients toward the appropriate primary care team before regenerative medicine is considered.